Repetitive transcranial magnetic stimulation (rTMS) is approved by the US Food and Drug Administration (FDA) for treatment resistant depression (TRD), and presumably works by modulating brain circuitry. A new meta-analysis focuses specifically on using rTMS as augmentation to antidepressants in patients with TRD.

You can't view details of this content, please login or buy subscription here